Infant formula palmitic acid sn-2 positioning
Solution Overview
Problem
Current infant formulas with high palmitic acid esterified in the sn-1(3) position of triacylglycerols lead to increased calcium excretion and harder stools due to the formation of insoluble calcium-palmitic acid complexes, which is not seen in human breast milk, where palmitic acid is predominantly esterified in the sn-2 position.
Innovation Solution
A composition for infant formulas with a moderate amount (20-60%) of palmitic acid esterified in the sn-2 position of triacylglycerols and a higher amount (40-80%) in the sn-1(3) position, combined with partially hydrolysed protein, to mimic the lipid profile of human milk, reducing calcium excretion and promoting better nutrient absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If infant formulas use high palmitic acid content (80% sn-1(3) position) to match human milk lipid composition, then calcium excretion increases and stool hardness worsens due to insoluble calcium-palmitic acid complex formation
Solution Approach 1:
The patent applies local quality by specifically controlling the regiospecific distribution of palmitic acid within the lipid structure. Instead of uniformly distributing palmitic acid, the invention places it predominantly (at least 65%) in the sn-2 position of triacylglycerols, while limiting sn-1(3) position content to no more than 35%. This localized placement strategy mimics human breast milk composition and prevents calcium soap formation, thereby resolving the contradiction between maintaining high palmitic acid content and avoiding harmful calcium excretion effects.
2Ease of manufacture
If infant formulas use moderate sn-2 palmitate content (20-60%) to simplify manufacturing, then calcium absorption improves and soap formation reduces
Solution Approach 1:
The patent applies parameter changes by establishing specific quantitative thresholds for palmitic acid distribution: at least 65% in sn-2 position and no more than 35% in sn-1(3) position. These parameter specifications optimize both manufacturing feasibility and calcium absorption efficiency. The defined ranges balance the complexity of lipid processing with the physiological requirement for reduced calcium soap formation, thereby resolving the contradiction between ease of manufacture and reliability of calcium absorption.
3Adaptability or versatility
If infant formulas use high sn-1(3) palmitate content to simplify oil selection, then digestive comfort worsens due to increased palmitic acid soap formation
Solution Approach 1:
The patent applies local quality by precisely controlling where palmitic acid is positioned within the triacylglycerol molecule. By limiting sn-1(3) position content to no more than 35% and placing at least 65% in the sn-2 position, the invention creates a localized distribution pattern that prevents harmful interactions between palmitic acid and calcium. This resolves the contradiction between oil source flexibility and digestive comfort, as the regiospecific placement prevents soap formation regardless of the vegetable oil source used.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition results in calcium excretion levels similar to those of breastfed infants, improving calcium absorption, reducing the formation of palmitic acid soaps, and alleviating digestive discomfort, constipation, and enhancing bone mineralization.
Implementation Method 1
The present invention relates to a composition for use in formulaes for infants or young children comprising partially hydrolysed protein
Data Source
AI summary
The present invention relates to a composition for use in formulae for infants or young children comprising partially hydrolysed protein and an oil mix comprising palmitic acid wherein the palmitic acid esterified in the sn-2 position of triacylglycerols is in the amount of from 20% to 60% by weight of total palmitic acid. Furthermore, the invention relates to an infant formula comprising said composition and the use of said composition or infant formula.